OTCPK:ITMM.F

Stock Analysis Report

Executive Summary

Itamar Medical Ltd. engages in the research, development, marketing, sale, and leasing of non-invasive medical devices for the cardiology market in the United States and Canada, Europe, Israel, Japan, the Asia Pacific, and internationally.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.

Risks

  • Itamar Medical has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Itamar Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:ITMM.F

0.5%

US Medical Equipment

-0.02%

US Market


1 Year Return

14.9%

OTCPK:ITMM.F

9.9%

US Medical Equipment

1.6%

US Market

ITMM.F outperformed the Medical Equipment industry which returned 9.7% over the past year.

ITMM.F outperformed the Market in United States of America which returned 1.9% over the past year.


Share holder returns

ITMM.FIndustryMarket
7 Day0%0.5%-0.02%
30 Day-19.3%0.09%2.7%
90 Day-10.8%2.0%1.4%
1 Year14.9%14.9%10.8%9.9%3.8%1.6%
3 Yearn/a69.0%63.9%45.2%35.8%
5 Year-48.1%-48.1%136.2%109.3%61.8%44.1%

Price Volatility Vs. Market

How volatile is Itamar Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Itamar Medical undervalued based on future cash flows and its price relative to the stock market?

5.54x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Itamar Medical to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Itamar Medical to establish if it is available at substantial discount.


Price Based on Earnings

Itamar Medical is loss making, we can't compare its value to the US Medical Equipment industry average.

Itamar Medical is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Itamar Medical, we can't assess if its growth is good value.


Price Based on Value of Assets

Itamar Medical is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Itamar Medical expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

29.4%

Forecasted annual revenue growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Itamar Medical's revenue is expected to grow significantly at over 20% yearly.

Unable to determine if Itamar Medical is high growth as no earnings estimate data is available.

Itamar Medical's revenue growth is expected to exceed the United States of America market average.

Unable to compare Itamar Medical's earnings growth to the United States of America market average as no estimate data is available.

Unable to compare Itamar Medical's earnings growth to the low risk savings rate as no estimate data is available.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Itamar Medical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Itamar Medical performed over the past 5 years?

13.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Itamar Medical does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Itamar Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Itamar Medical's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Itamar Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Itamar Medical has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Itamar Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Itamar Medical's financial position?


Financial Position Analysis

Itamar Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Itamar Medical's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Itamar Medical's level of debt (27.6%) compared to net worth is satisfactory (less than 40%).

Itamar Medical had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 5.6x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Itamar Medical has sufficient cash runway for more than 3 years based on current free cash flow.

Itamar Medical has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -41.1% each year.


Next Steps

Dividend

What is Itamar Medical's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Itamar Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Itamar Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Itamar Medical has not reported any payouts.

Unable to verify if Itamar Medical's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Itamar Medical has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Itamar Medical's salary, the management and board of directors tenure and is there insider trading?

6.2yrs

Average management tenure


CEO

Gilad Glick (46yo)

6.2yrs

Tenure

US$939,000

Compensation

Mr. Gilad Glick has been the Chief Executive Officer of Itamar Medical Ltd., since July 1, 2013 and serves as its President. Prior to joining Itamar Medical, Mr. Glick held 18 year career in Medical Device ...


CEO Compensation Analysis

Gilad's remuneration is higher than average for companies of similar size in United States of America.

Gilad's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

6.2yrs

Average Tenure

48.5yo

Average Age

The average tenure for the Itamar Medical management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

5.2yrs

Average Tenure

71yo

Average Age

The tenure for the Itamar Medical board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Martin Gerstel (78yo)

    Director

    • Tenure: 22.7yrs
    • Compensation: US$68.00k
  • Shlomo Ayanot (63yo)

    Vice President of Engineering & Operations

    • Tenure: 20.7yrs
  • Daphna Triwaks

    Head of Public Relations

    • Tenure: 0yrs
  • Gilad Glick (46yo)

    President

    • Tenure: 6.2yrs
    • Compensation: US$939.00k
  • Ira Prigat (50yo)

    VP & President of Itamar Medical Japan Co Ltd

    • Tenure: 0yrs
    • Compensation: US$1.17m
  • Shy Basson (47yo)

    Chief Financial Officer

    • Tenure: 2.3yrs
    • Compensation: US$403.00k
  • Shahar Cohen (43yo)

    Controller

    • Tenure: 0yrs

Board Members

  • Yaffa Krindel (64yo)

    External Director

    • Tenure: 3.7yrs
    • Compensation: US$30.00k
  • Giora Yaron (71yo)

    Chairman of the Board

    • Tenure: 0yrs
    • Compensation: US$362.00k
  • Martin Gerstel (78yo)

    Director

    • Tenure: 22.7yrs
    • Compensation: US$68.00k
  • Ilan Biran (73yo)

    Director

    • Tenure: 6.7yrs
    • Compensation: US$76.00k
  • Tzipi Ozer-Armon (58yo)

    External Director

    • Tenure: 3.7yrs
    • Compensation: US$30.00k
  • Amir Lerman

    Member of Advisory Board

    • Tenure: 0yrs
  • Peter Gantz

    Member of Advisory Board

    • Tenure: 0yrs
  • Michael Shechter

    Member of Advisory Board

    • Tenure: 0yrs
  • Peter Collins

    Member of Advisory Board

    • Tenure: 0yrs
  • Kirk Garratt

    Member of Advisory Board

    • Tenure: 0yrs

Company Information

Itamar Medical Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Itamar Medical Ltd.
  • Ticker: ITMM.F
  • Exchange: OTCPK
  • Founded: 1997
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: ₪354.043m
  • Listing Market Cap: ₪100.259m
  • Shares outstanding: 334.00m
  • Website: https://www.itamar-medical.com

Number of Employees


Location

  • Itamar Medical Ltd.
  • 9 Halamish Street
  • North Industrial Zone
  • Caesarea
  • 3088900
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ITMRTASE (The Tel-Aviv Stock Exchange)YesOrdinary SharesILILSMar 2007
ITMM.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMar 2007
ITMRNasdaqCM (Nasdaq Capital Market)SPONSORED ADSUSUSDFeb 2019

Biography

Itamar Medical Ltd. engages in the research, development, marketing, sale, and leasing of non-invasive medical devices for the cardiology market in the United States and Canada, Europe, Israel, Japan, the  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/19 00:21
End of Day Share Price2019/09/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.